Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC

Video content above is prompted by the following:

CNS Progression Management

Key Themes:

• Brain Metastases Protection: Strategies to prevent and manage CNS progression
• Treatment Selection Impact: How CNS protection factors into first- and second-line treatment decisions
• Antibody-Drug Conjugates: Emerging data on CNS activity of antibody-drug conjugates in EGFR-mutated disease

Notable Insights:

• Dr Dietrich: Was “very positively surprised” that amivantamab showed brain protection, noting it “seemed to have related to patients that had treated and untreated brain metastases as well.” He identified brain metastases as “both psychologically and somatically associated with a decline in quality of life.”
• Dr Piotrowska: Supported osimertinib continuation for patients with well-controlled CNS disease who develop systemic progression. She emphasized the importance of “surveillance brain imaging on these patients, even periodically, if they didn’t have CNS disease at initial diagnosis.”